Changes in Industrial Structure Adjustment Catalog: Inclusion of E-Cigarettes

Regulations by 2FIRSTS
Dec.29.2023
Changes in Industrial Structure Adjustment Catalog: Inclusion of E-Cigarettes
The National Development and Reform Commission officially released a revised industrial restructuring guide, including e-cigarettes.

On December 29, 2023, the National Development and Reform Commission (NDRC) officially released the "Guidance Catalog for Industrial Restructuring (2024 Edition)" (hereinafter referred to as the Catalog).

 

Changes in Industrial Structure Adjustment Catalog: Inclusion of E-Cigarettes
"Guidance Catalog 2023 (Opinion Solicitation Draft) File Screenshot

 

The term "e-cigarette" is mentioned for the first time in the directory. However, compared to the draft of the "Guidance Catalog for Industrial Structure Adjustment (2023, for soliciting opinions)" released in July 2023, there have been adjustments regarding the portrayal of e-cigarettes.

 

Changes in Industrial Structure Adjustment Catalog: Inclusion of E-Cigarettes
Screenshot of the "Guiding Catalogue for Industrial Structural Adjustment (2024 Edition)" document.

 

The statement for public opinion solicitation states: tobacco products, including e-cigarettes and other new types of tobacco products.

 

The official release refers to new tobacco products such as e-cigarettes.

 

Previously, 2FIRSTS reported on the inclusion of e-cigarettes in the "Guidance Catalog for Industrial Structure Adjustment (2023 Edition, Draft for Soliciting Opinions)".

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

FDA Authorizes Glas Vape but Flavor Hopes Fall Short
FDA Authorizes Glas Vape but Flavor Hopes Fall Short
The FDA has added Glas products to its authorized electronic nicotine delivery systems (ENDS) list, granting Marketing Granted Orders (MGOs) to the Glas G DEVICE and a BLONDE TOBACCO pod. The decision expands the number of FDA-authorized ENDS products to 41, marking the first new authorization since Juul’s approvals in July 2025. However, widely anticipated non-tobacco flavored products were not approved.
Mar.13
Six Years of Data Show FDA Clearing PMTA Backlog
Six Years of Data Show FDA Clearing PMTA Backlog
FDA data from FY2020 to FY2025 show how the PMTA system for e-cigarette products evolved after an early surge of submissions created prolonged front-end delays. Millions of applications accumulated at the Acceptance stage before entering substantive review. Since 2023, the number of applications pending acceptance has declined sharply, and industry participants report shorter initial decision timelines in late 2025.
Feb.06
Two Florida Bills Move: One Restricts Vape Advertising, Another Rewrites Cigarette Tax Treatment for Heated Tobacco
Two Florida Bills Move: One Restricts Vape Advertising, Another Rewrites Cigarette Tax Treatment for Heated Tobacco
The Florida Senate Industries Committee advance SB 980, the “Florida Age-Gate Act,” which would restrict advertising, promotion, and open displays of certain nicotine dispensing devices that lack FDA marketing authorization, with escalating penalties. Separately, the Florida House Ways and Means Committee advance HB 377, which would exclude heated tobacco products from being taxed like cigarettes.
Jan.28 by 2FIRSTS.ai
Hampshire Trading Standards Seizes £138,000 Worth of Illegal Vapes and Tobacco in 2025
Hampshire Trading Standards Seizes £138,000 Worth of Illegal Vapes and Tobacco in 2025
According to Hampshire County Council, its Trading Standards team confiscated 116,000 illegal vape and tobacco products in 2025, worth an estimated £138,000 — a record annual haul.
Feb.02 by 2FIRSTS.ai
Scandinavian Tobacco Group releases 2025 results: tariffs and weaker demand weigh on performance, revenue about $1.4 billion
Scandinavian Tobacco Group releases 2025 results: tariffs and weaker demand weigh on performance, revenue about $1.4 billion
Scandinavian Tobacco Group (STG) reported its 2025 results: revenue was 9.036 billion Danish kroner (about $1.407 billion); EBITDA before special items was 1.791 billion Danish kroner (about $278 million); and free cash flow before acquisitions was 595 million Danish kroner (about $92.7 million). Multiple metrics declined year over year, and the company did not meet its Q3-updated guidance for revenue and free cash flow.
Mar.05 by 2FIRSTS.ai
FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA officials said manufacturing consistency is a core prerequisite for ENDS PMTA reviews, not a procedural formality. During its February 10, 2026 roundtable, the agency outlined expectations for quality management systems, manufacturing documentation, nicotine control, stability studies, and risk mitigation, emphasizing that robust manufacturing evidence underpins determinations of whether products are appropriate for the protection of public health.
Feb.11